On Monday, Veeva Systems Inc (NYSE:VEEV)’s shares inclined 0.33% to $24.28.
Veeva Systems Inc. (VEEV) declared it has attained Zinc Ahead, a leading provider of commercial content administration solutions. Veeva and Zinc Ahead are joining forces to address the growing need for end-to-end compliance administration that reduces regulatory risk and boosts operational efficiency as companies face increasing volumes of content, a proliferation of digital channels, and raised regulatory scrutiny.
The combination brings together two of the leading commercial content administration solutions. Zinc Ahead, founded in 2001, was an early pioneer in the market serving more than 120 life sciences companies with Zinc MAPS. Veeva Systems’ solution—Vault PromoMats released in 2011—is now utilized by more than 70 customers.
With this acquisition, the market will now have a powerful, end-to-end solution that combines the strengths of both Veeva and Zinc Ahead. The joint company will fully support Zinc Ahead customers with the outstanding levels of personalized service for which Zinc Ahead is known. Customers will have access to an improved Vault PromoMats solution, bolstered by the unique strengths of Zinc Ahead’s offerings. The result will be the most complete software and services solution for digital content creation, review, and multichannel approval and withdrawal on the market—backed by a company-wide commitment to customer success.
Veeva Systems Inc. provides cloud-based software solutions for the life sciences industry in North America, Europe, the Asia Pacific, and Latin America.
Albemarle Corporation (NYSE:ALB)’s shares gained 2.80% to $47.44.
The board of directors of Albemarle Corporation (ALB) declared a quarterly dividend of $0.29 per share. The dividend is payable January 4, 2016, to shareholders of record at the close of business as of December 15, 2015.
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. The company’s Performance Chemicals segment offers brominated flame retardants under the Saytex brand; mineral-based flame retardants under the Martinal and Magnifin brands; and various other industrial applications.
At the end of Monday’s trade, Anthera Pharmaceuticals Inc (NASDAQ:ANTH)‘s shares dipped -1.43% to $6.20.
Anthera Pharmaceuticals, Inc. (ANTH) declared the initiation of the SOLUTION (Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in People With Cystic Fibrosis) Phase 3 clinical study evaluating the efficacy and safety of Sollpura(R) (liprotamase), a microbial derived, biotech pancreatic enzyme replacement therapy (PERT), contrast to an approved, porcine-derived, enteric-coated product for the treatment of exocrine pancreatic insufficiency (EPI).
The Phase 3 SOLUTION clinical study is a multicenter, randomized, open-label, assessor-blind, non-inferiority, active-comparator study designed to evaluate the efficacy and safety of Sollpura in people with EPI due to cystic fibrosis. This pivotal study is intended to evaluate the non-inferiority of Sollpura contrast with a commercially accessible PERT in a population enriched for PERT responders. The primary efficacy endpoint of this study will be comparative efficacy measured as the change in the coefficient of fat absorption (CFA) at the end of therapy.
On Friday October 9th, 2015 from 8:00 to 10:00 PM, during the North American Cystic Fibrosis Conference, Anthera will host a reception to talk about the SOLUTION clinical study with Sollpura. The reception will be held at the Sheraton hotel, 340 N 3rd Street, Phoenix, Arizona. To receive an invitation to the event, please contact Nikhil Agarwal at [email protected], proceeding to Wednesday, October 7th, 2015.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs.
Crown Holdings, Inc. (NYSE:CCK), ended its Monday’s trading session with 0.32% gain, and closed at $47.52.
Crown Holdings, Inc. (CCK) (Crown) a leading supplier of metal packaging products worldwide, declared it is investing in a second line at its Osmaniye plant, in central southern Turkey, to produce aluminum beverage cans. The plant presently produces 800 million beverage cans, serving customers in Turkey and neighboring markets.
Crown operates two beverage can plants in Turkey, in Izmit and Osmaniye, manufacturing a wide range of aluminum can sizes. Crown is installing the new capacity in response to growing demand in Turkey, where sales of empty beverage cans exceeded 2.6 billion units last year, and surrounding countries.
The new line is predictable to be operational in the first quarter of 2017 and have initial annual production capacity of about 900 million two-piece aluminum beverage cans in multiple sizes. The additional line will more than double the Osmaniye plant’s annual production capacity to over 1.7 billion cans.
Crown Holdings, Inc. designs, manufactures, and sells packaging products for consumer goods in Americas, Europe, and the Asia Pacific.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
